Meniscal Repair Innovator Continues U.S. Growth MINNEAPOLIS and MISGAV, Israel, Aug. 5, 2024 /PRNewswire/ -- Arcuro Medical Ltd., ("Arcuro") today announced a key milestone of exceeding 4,000 surgical cases worldwide, and 1,000 cases in the U.S., with its SuperBall™ Meniscal Repair System. The current version of the SuperBall Meniscal Repair System, commercially launched in 2022, with additional line extensions introduced in late 2023 addresses a full range of meniscus tear patterns. Jamal Rushdy, Arcuro's ...

Group 1 - Dominic (Dom) Serafino has been appointed as the Executive Chair of Dasyo, bringing extensive experience from his previous role as Co-Founder and CEO of Venus Concept Inc., where he led the company to over $100 million in annual revenues [1][2] - The appointment of Serafino is seen as a transformative step for Dasyo, aligning with the company's ambitious objectives in the aesthetics medical device sector [2] - Dasyo is focused on developing innovative non-surgical breast lift products utilizing proprietary technology for noninvasive directional skin tightening, supported by funding from the Israel Innovation Authority and The Trendlines Group [4] Group 2 - Serafino has a notable background, having been part of the executive team at Syneron Medical Corp, where he played a key role in the company's IPO, achieving a market cap of $1.3 billion within 18 months [5] - Serafino expressed confidence in Dasyo's innovative approach to aesthetics medical technologies, particularly in the non-surgical breast lifting category [6]

Core Insights - Ceretrieve's aspiration catheter has demonstrated the ability to remove clots and restore blood flow in a single pass, showcasing significant advancements in stroke treatment [1][2][4] Company Overview - Ceretrieve aims to transform stroke care by minimizing disability and improving post-stroke quality of life through innovative medical devices [2][6] - The company was established in 2017 in collaboration with The Trendlines Group and the Israel Innovation Authority [6] Study Results - A multicenter, single-arm study involving 20 patients showed that the Ceretrieve device achieved 100% Complete/Near-Complete Perfusion in all treated patients using the improved Gen 2 device [4] - The device achieved an 83% First Pass Complete Perfusion rate, significantly higher than the 30%-40% rate of current gold-standard devices [4][3] Device Features - The aspiration catheter is designed for seamless integration with conventional delivery systems, offering exceptional trackability and maneuverability [2][5] - The device features a giant bore tip that enhances vacuum effect while maintaining trackability, and it provides local flow restriction to reduce distal emboli [5] Clinical Impact - The first pass effect of the Ceretrieve device has been shown to improve patient outcomes, enabling complete clot ingestion even in challenging cases [5] - The advanced technology of Ceretrieve is setting a new standard in stroke care, leading to significant improvements in patient recovery rates [5]